Premium
Impact of the patient's body weight on the efficacy and adverse events of valganciclovir for cytomegalovirus reactivation after hematopoietic stem cell transplantation
Author(s) -
Misaki Yukiko,
Kimura Shunichi,
Kawamura Masakatsu,
Kawamura Shunto,
Takeshita Junko,
Yoshino Nozomu,
Yoshimura Kazuki,
Gomyo Ayumi,
Matsumi Shimpei,
Akahoshi Yu,
Tamaki Masaharu,
Kusuda Machiko,
Kameda Kazuaki,
Wada Hidenori,
Kawamura Koji,
Sato Miki,
TerasakoSaito Kiriko,
Tanihara Aki,
Nakasone Hideki,
Kako Shinichi,
Kanda Yoshinobu
Publication year - 2020
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.13270
Subject(s) - valganciclovir , medicine , ganciclovir , cytomegalovirus , adverse effect , gastroenterology , transplantation , white blood cell , hematopoietic stem cell transplantation , creatinine , urology , immunology , human cytomegalovirus , herpesviridae , virus , viral disease
While the dose of ganciclovir (GCV) is decided base on patients' body weight (BW), that of valganciclovir (VGCV) is fixed as 900 or 1800 mg/d regardless of the patient's BW in preemptive therapy for cytomegalovirus (CMV) reactivation in hematopoietic stem cell transplantation. We analyzed the impact of the patient's BW on the effectiveness and adverse events (AEs) of VGCV. From March 2004 to February 2017, 27 patients received VGCV as a first‐line treatment for CMV reactivation. As a historical control group, we extracted 17 patients who started to receive GCV at a similar timing. We used the following definitions of outcomes: speed of reduction of CMV antigenemia (CMV‐AG) as a measure of effectiveness, ratios of baseline and minimum value for white blood cell (WBC) and platelet counts, and ratio of baseline and maximum values for serum creatinine (sCr) as measures of AEs. As a result, there was no significant correlation between average daily dose of VGCV with or without adjusting for the patient's BW and speed of reduction of CMV‐AG. On the other hand, the decreases in WBC and platelets and the increase in sCr were significantly correlated with the cumulative dose of VGCV. However, the absolute values of the correlation coefficients did not increase when we analyzed the correlations between the BW‐adjusted cumulative dose of VGCV and factors associated with adverse events. There were no significant differences in efficacies or AE parameters between the GCV and VGCV groups. In conclusion, the patient's BW did not significantly affect the effectiveness or adverse events of VGCV.